Slideshow

Rate of MetS Unchanged after One Year of GH Replacement

Author(s):

Gregory M. Weiss, MD

Results of a new study highlight the importance of intensive treatment of all comorbidities associated with adult growth hormone deficiency.

Related Videos
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Rahul Aggarwal, MD | Credit: LinkedIn
Brendon Neuen, MBBS, PhD | Credit: X.com
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
Optimizing Diabetes Therapies with New Classifications
Related Content
Intensive Blood Pressure Regimen Lowers CVD Risk in People with T2D | Image Credit: American Heart Association
November 16th 2024

Intensive Blood Pressure Regimen Lowers CVD Risk in People with T2D

Connor Iapoce
Diabetes Dialogue: Diabetes Tech Updates in October 2024
November 11th 2024

Diabetes Dialogue: Diabetes Tech Updates in October 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Henning Bliddal, MD, MSci., The Parker Institute, Copenhagen University Hospital, Denmark
November 1st 2024

Semaglutide Reduces Knee Osteoarthritis Pain in People With Obesity

Victoria Johnson
Diabetes Dialogue: Tidepool Updates, with Brandon Arbiter
November 8th 2024

Diabetes Dialogue: Tidepool Updates, with Brandon Arbiter

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center
October 21st 2024

Oral Semaglutide Reduces MACE Risk in People With Type 2 Diabetes and CVD

Victoria Johnson
US FDA LOGO IN BLACK OVER A WHITE BACKGROUND. | Credit: US Food and Drug Administration
October 8th 2024

FDA Issues Second CRL for Dasiglucagon (Zegalogue) in Congenital Hyperinsulinism

Patrick Campbell
© 2024 MJH Life Sciences

All rights reserved.